AbbVie Inc (ABBV)vsViking Holdings Ltd (VIK)
ABBV
AbbVie Inc
$209.40
-0.81%
HEALTHCARE · Cap: $370.38B
VIK
Viking Holdings Ltd
$68.58
-4.20%
CONSUMER CYCLICAL · Cap: $32.40B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 841% more annual revenue ($61.16B vs $6.50B). VIK leads profitability with a 17.6% profit margin vs 6.9%. VIK trades at a lower P/E of 28.3x. VIK earns a higher WallStSmart Score of 66/100 (B-).
ABBV
Buy63
out of 100
Grade: C+
VIK
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1199.0%
Fair Value
$16.12
Current Price
$209.40
$193.28 premium
Margin of Safety
+36.3%
Fair Value
$120.28
Current Price
$68.58
$51.70 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Strong operational efficiency at 20.9%
Revenue surging 27.8% year-over-year
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
Moderate valuation
2.3% earnings growth
ROE of 2.5% — below average capital efficiency
Trading at 28.0x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.50 suggests the stock is reasonably priced for its growth.
Bull Case : VIK
The strongest argument for VIK centers on Operating Margin, Revenue Growth. Profitability is solid with margins at 17.6% and operating margin at 20.9%. Revenue growth of 27.8% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 88.3x leaves little room for execution misses.
Bear Case : VIK
The primary concerns for VIK are P/E Ratio, EPS Growth, Return on Equity.
Key Dynamics to Monitor
ABBV profiles as a value stock while VIK is a growth play — different risk/reward profiles.
VIK is growing revenue faster at 27.8% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
VIK scores higher overall (66/100 vs 63/100), backed by strong 17.6% margins and 27.8% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Viking Holdings Ltd
CONSUMER CYCLICAL · TRAVEL SERVICES · USA
Viking Holdings Ltd engages in the passenger shipping and other forms of passenger transport in North America, the United Kingdom, and internationally. The company is headquartered in Pembroke, Bermuda.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?